News headlines about Cambrex Corporation (NYSE:CBM) have trended positive recently, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cambrex Corporation earned a daily sentiment score of 0.26 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 48.1060546951981 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the media headlines that may have effected Accern’s analysis:

A number of equities research analysts recently commented on the company. BidaskClub downgraded Cambrex Corporation from a “buy” rating to a “hold” rating in a report on Saturday, August 12th. Zacks Investment Research raised Cambrex Corporation from a “hold” rating to a “buy” rating and set a $59.00 price target for the company in a report on Thursday, May 11th. Finally, ValuEngine downgraded Cambrex Corporation from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $64.00.

Shares of Cambrex Corporation (NYSE:CBM) traded down 0.58% on Friday, reaching $51.70. The company’s stock had a trading volume of 111,146 shares. The company has a market capitalization of $1.69 billion, a price-to-earnings ratio of 18.83 and a beta of 2.28. Cambrex Corporation has a 1-year low of $38.30 and a 1-year high of $62.95. The stock has a 50-day moving average price of $57.64 and a 200-day moving average price of $55.46.

Cambrex Corporation (NYSE:CBM) last posted its quarterly earnings data on Friday, August 4th. The biotechnology company reported $0.76 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.76. Cambrex Corporation had a return on equity of 24.25% and a net margin of 17.70%. The company had revenue of $134.55 million during the quarter, compared to analysts’ expectations of $136.82 million. During the same period last year, the firm earned $0.68 EPS. The firm’s revenue for the quarter was up 13.4% on a year-over-year basis. On average, equities research analysts forecast that Cambrex Corporation will post $3.08 EPS for the current year.

In other Cambrex Corporation news, Director Leon J. Hendrix, Jr. sold 20,656 shares of the stock in a transaction that occurred on Tuesday, June 6th. The stock was sold at an average price of $55.95, for a total transaction of $1,155,703.20. Following the completion of the sale, the director now directly owns 74,662 shares of the company’s stock, valued at approximately $4,177,338.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Samantha Hanley sold 14,000 shares of the stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $57.56, for a total value of $805,840.00. Following the sale, the vice president now directly owns 1,500 shares of the company’s stock, valued at $86,340. The disclosure for this sale can be found here. Insiders have sold a total of 70,656 shares of company stock valued at $4,064,423 over the last ninety days. 2.48% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at

About Cambrex Corporation

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Insider Buying and Selling by Quarter for Cambrex Corporation (NYSE:CBM)

Receive News & Stock Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related stocks with our FREE daily email newsletter.